Exhibit 1



Important Disclaimer Information



ABOUT VISION ONE

Vision One Fund, LP (together with its affiliates, "Vision One") is a value-focused, governance-oriented investment firm based in Miami, Florida. Our objective is to generate private equity returns with public market liquidity in the Consumer and Industrial sectors by identifying high-quality businesses selling at a steep discount, partnering with companies, boards, and management teams, and instilling best governance practices that benefit all stockholders.

NOTE REGARDING THIS COMMUNICATION

THIS COMMUNICATION IS PROVIDED MERELY AS INFORMATION AND IS NOT INTENDED TO BE, NOR SHOULD IT BE CONSTRUED AS, AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY NOR AS A RECOMMENDATION TO PURCHASE OR SELL ANY SECURITY.

THIS COMMUNICATION CONTAINS VISION ONE'S CURRENT VIEWS ON THE VALUE OF INGEVITY'S SECURITIES AND ACTIONS THAT HAVE BEEN TAKEN OR MAY BE TAKEN BY INGEVITY IN ORDER TO ENHANCE THE VALUE OF INGEVITY'S SECURITIES. VISION ONE'S VIEWS ARE BASED ON PUBLICLY AVAILABLE INFORMATION WITH RESPECT TO INGEVITY AND ASSUMPTIONS THAT VISION ONE DEEMS TO BE REASONABLE. THERE IS NO ASSURANCE THAT THE INFORMATION VISION ONE CONSIDERED AND ANALYZED IS ACCURATE OR COMPLETE. IN ADDITION, THERE IS NO ASSURANCE THAT VISION ONE'S ASSUMPTIONS ARE CORRECT. INGEVITY'S PERFORMANCE AND RESULTS MAY DIFFER MATERIALLY FROM VISION ONE'S ASSUMPTIONS AND ANALYSIS.

VISION ONE RESERVES THE RIGHT TO CHANGE ANY OF ITS OPINIONS EXPRESSED HEREIN AT ANY TIME AS IT DEEMS APPROPRIATE AND DISCLAIMS ANY OBLIGATION TO NOTIFY THE MARKET OR ANY OTHER PARTY OF ANY SUCH CHANGE, EXCEPT AS REQUIRED BY LAW. VISION ONE DISCLAIMS ANY OBLIGATION TO UPDATE THE INFORMATION OR OPINIONS CONTAINED IN THIS COMMUNICATION. VISION ONE AND ITS AFFILIATES BENEFICIALLY OWN SECURITIES ISSUED BY INGEVITY. VISION ONE MAY SELL ANY OR ALL OF ITS HOLDINGS OR INCREASE ITS HOLDINGS BY PURCHASING ADDITIONAL SECURITIES OF INGEVITY. VISION ONE MAY TAKE ANY OF THESE OR OTHER ACTIONS REGARDING INGEVITY WITHOUT UPDATING THIS COMMUNICATION OR PROVIDING ANY NOTICE WHATSOEVER OF ANY SUCH CHANGES, EXCEPT AS REQUIRED BY LAW.

VISION ONE HAS NOT SOUGHT, NOR HAS IT RECEIVED, PERMISSION FROM ANY THIRD-PARTY TO INCLUDE THEIR INFORMATION IN THIS COMMUNICATION. ANY SUCH INFORMATION SHOULD NOT BE VIEWED AS INDICATING THE SUPPORT OF SUCH THIRD PARTY FOR THE VIEWS EXPRESSED HEREIN.

- 12

Additional Disclaimer Information



Additional Information and Where to Find It; Participants in the Solicitation and Notice to Investors

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY VISION ONE FUND, LP AND ITS AFFILIATES (COLLECTIVELY, "VISION ONE") FROM THE STOCKHOLDERS OF INGEVITY CORPORATION ("INGEVITY") FOR USE AT ITS 2025 ANNUAL MEETING OF STOCKHOLDERS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN SUCH PROXY SOLICITATION. WHEN COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE MAILED TO STOCKHOLDERS OF INGEVITY AND WILL ALSO BE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV. INFORMATION RELATING TO THE PARTICIPANTS IN SUCH PROXY SOLICITATION IS CONTAINED IN THE SCHEDULE 14A FILED BY VISION ONE WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 25, 2025. EXCEPT AS OTHERWISE DISCLOSED IN THE SCHEDULE 14A, THE PARTICIPANTS HAVE NO INTEREST IN INGEVITY.

FORWARD-LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements including, but not limited to, statements that are predications of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties. The projected results and statements contained herein that are not historical facts are based on current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Vision One.

Forward-looking statements can be identified by the use of the future tense or other forward-looking words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "should," "could," "may," "will," "projection," "forecast," "strategy," "position" and other similar expressions, including the negative of such terms. Similarly, statements that describe our objectives, plans or goals are forward-looking. Accordingly, forward-looking statements should not be regarded as a representation by Vision One that the future plans, estimates or expectations contemplated will ever be achieved. Important factors that could cause actual results to differ materially from the expectations set forth in this communication include, among other things, the factors identified in Ingevity's public filings. Such forward-looking statements should therefore be construed in light of such factors, and Vision One is under no obligation, and expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Ingevity ("NGVT") Today



- Legacy Board members have presided over nearly nine years of bad acquisitions and erratic corporate strategy
- · Undisciplined capital allocation has sharply reduced returns on capital and free cash flow
- Lack of effective leadership has resulted in worst-in-class Total Shareholder Return ("TSR")
- Appointment of legacy Board member as Interim CEO confirms lack of credible succession plan
- · Recent Company actions are reactive pivot to shareholder concerns
- The Company's plan to exit Industrial Specialties further obfuscates corporate strategy
- Shares are trading at record low valuation multiples reflecting lack of confidence in the Board
- · We believe that legacy directors will continue to seek like-minded individuals, including any new CEO
- We have nominated four highly-qualified director candidates to drive change, restore good governance, implement value-enhancing
 capital allocation, and ensure stockholder input into CEO selection

[&]quot;Legacy Board members" refers to Jean Blackwell, Dan Sansone, Luis Fernandez-Moreno, and Fred Lynch
Valuation multiples: December 2016 through February 2025 trailing Price to Earnings, Price to Free Cash Flow, and Enterprise Value to EBITDA trailing multiples sourced from Bloomberg
as of February 24, 2025. All three referenced valuation metrics at the lowest level in the Company's history (10.4x Price to Earnings, 8.8x Price to Free Cash Flow, 7.4x Enterprise Value to
EBITDA as of market close February 24, 2025)

Our Vision: Unveil an Industrial Powerhouse



We believe that NGVT shares are worth \$124 per share and offer over 165% upside

- Value of premier Performance Materials segment is obscured by chemical assets
- · Fair valuation of Performance Materials is only possible through full exit of Performance Chemicals segment
- · New governance safeguards will reinstill discipline and fix legacy oversight deficiencies
- Shareholder input on CEO selection is crucial to stop perpetuation from legacy Board members
- We believe that our initiatives, led by Vision One's director nominees, will generate immense value for all NGVT shareholders

Lax Legacy Oversight Requires Immediate Accountability



Entrenched Board of legacy directors (Jean Blackwell, Dan Sansone, Luis Fernandez-Moreno, and Fred Lynch) will continue to maintain status quo:

Misguided Capital Allocation

- Poor track record of capital deployment that is long and clear
- Overpaid for acquisitions then subsequently shut down assets at a substantial loss
- Now advocate for disgorgement of one of their approved acquisitions at fire sale value
- Produced an estimated loss of \$872 million on \$1.8 billion of acquisition and share repurchase spending

Existing Board has failed to implement an effective corporate strategy; new directors are needed to oversee disciplined capital allocation

Further Entrenchment with CEO Selection

- Self-selected one of their own to serve as Interim CEO with an extravagant compensation package
- Same Board is now charged with selection of a new CEO

Stockholder representation on the Board is crucial to ensuring objective CEO selection

Lack of Accountability to Shareholders

- Presided over 50% declines in free cash flow per share and Return on Invested Capital
- Have remained complacent with corporate governance standards and integrity of Board process
- Consistently exhibited weak shareholder alignment with low stock ownership despite long tenures

Board refreshment necessary to demonstrate accountability, renew focus on corporate governance, and increase transparency

Without immediate and substantive Board refreshment, the status quo will continue

Estimated loss of \$872 million consists of \$703 million of value loss due to acquisition activity in addition to \$139 million of value loss due to share repurchases above NGVT's current share price. See slides 8 and 9 for additional detail

Stockholder Representation on Board Improves Oversight



Vision One is seeking Board representation to implement new governance safeguards

- Appoint Lead Independent Director to improve quality of Board process and challenge others
- Bolster alignment by adding direct shareholder representation to the Board
- Replace Executive Committee with Strategy and Finance Committee charged with development of returns-based capital allocation framework
- Establish director term limits
- Allow stockholders to act by written consent without holding a meeting
- Reduce the required ownership threshold to 10% for stockholders to call special meetings

New governance safeguards will reinstill discipline and fix legacy oversight deficiencies

Recent NGVT Actions Are Reactive Pivot to Vision One's Arrival



- November 26, 2024: Vision One sends private letter to NGVT's Board of Directors
- December 12, 2024: Vision One meets with legacy Board members Jean Blackwell and Luis Fernandez-Moreno
- December 26, 2024: NGVT elects Kevin Willis, a former co-worker of Mr. Luis
 Fernandez-Moreno, to the Board
- January 9, 2025: Vision One confirms intent to nominate directors
- January 16, 2025: NGVT announces plans to explore strategic alternatives for Industrial Specialties and releases preliminary 2024 results
 - Why did the Company hurriedly announce a strategic business exit?
 - Why did the Company release preliminary results just a month before its scheduled earnings release?
- January 23, 2025: Vision One nominates four highly-qualified director candidates
- February 18, 2025: NGVT reports full year 2024 financial results and discusses complex plan to split operating assets
 - If these are the right actions now, why weren't they done this way initially?
 - Actions are just admission of prior acquisition and strategy mistakes



Recent actions seek to insulate an already entrenched Board from concerns raised by stockholders

R

Years of Misguided Capital Allocation - M&A



- · Significant shift in NGVT's strategy and capital allocation began in 2018 with a confusing acquisition spree
- Each purchase was debt-financed and introduced new operating and financial risks across the enterprise with no corresponding increase in margin
 or profit
- · The transactions have delivered a loss of \$703 million with sharp and immediate performance declines

\$ million Company Acquired	Acquisition Date	Purchase Price	Current Value	Value Creation
Georgia-Pacific Pine Chemicals	March 2018	316	1.	(\$316)
Capa caprolactone division of Perstorp Holding AB	February 2019	651	264	(\$387)
Ozark Materials	October 2022	345	345	-
Total		\$1,312	\$609	(\$703)
% Loss				-54%

Georgia-Pacific

NGVT Claim

"Provide a stronger platform from which we will accelerate profitable growth"

Result

 Much of this business was subsequently shut down and cost shareholders an additional \$100 million in contract termination payments



NGVT Claim

· "Drive value creation to the benefit of our shareholders"

Result

· Capa's earnings have since declined by nearly half

Stockholder representation on the Board is critical to implementing an effective long-term strategy

Purchase prices derived from subsequent 10-K filing in the year following acquisition. Capa purchase price includes \$113 million of debt assumed as part of the transaction Georgia-Pacific Pine Chemicals' current value is estimated by Vision One as \$0 due to likely negative EBITDA and free cash flow, as well as being the reason for NGVT's \$100 million contract termination cash outlay

Capa caprolactone division of Perstorp Holding AB's current value is estimated by Vision One at \$264 million or 6x \$44 million of 2026 EBITDA
Capa caprolactone division of Perstorp Holding AB is now NGVT's Advanced Polymer Technologies segment

Years of Misguided Capital Allocation – Share Repurchase



- · Undisciplined deployment of surplus cash into stock buybacks has severely depleted returns on capital
- · The transactions have delivered a \$169 million loss

2017	2018	2019	2020	2021	2022	2023	2024	Total
7	47	6	88	109	145	92	1	495
0	1	0	2	1	2	1	-	7
\$66.28	\$84.49	\$80.22	\$57.39	\$76.97	\$68.73	\$72.56	-	\$69.95
								\$46.11
(2)	(22)	(3)	(17)	(44)	(48)	(34)	-	(169)
	7 0 \$66.28	7 47 0 1 \$66.28 \$84.49	7 47 6 0 1 0 \$66.28 \$84.49 \$80.22	7 47 6 88 0 1 0 2 \$66.28 \$84.49 \$80.22 \$57.39	7 47 6 88 109 0 1 0 2 1 \$66.28 \$84.49 \$80.22 \$57.39 \$76.97	7 47 6 88 109 145 0 1 0 2 1 2 \$66.28 \$84.49 \$80.22 \$57.39 \$76.97 \$68.73	7 47 6 88 109 145 92 0 1 0 2 1 2 1 \$66.28 \$84.49 \$80.22 \$57.39 \$76.97 \$68.73 \$72.56	7 47 6 88 109 145 92 - 0 1 0 2 1 2 1 - \$66.28 \$84.49 \$80.22 \$57.39 \$76.97 \$68.73 \$72.56 -

Strategy and Finance Committee is needed to implement appropriate capital allocation policy

Figures in table derived from NGVT 10-Ks and Proxy Statements

Value loss calculated as the difference of NGVT's current share price minus the average price paid per share multiplied by the number of shares repurchased

Years of Misguided Capital Allocation – Financial Impact



- · Financial metrics since inception show real impact of legacy Board members:
 - Free cash flow and Return on Invested Capital have been cut by more than half
 - Net debt and financial leverage have tripled

2017 2018 2019 2020 2021	Free Cash Flow per Share \$2.86 \$3.71 \$3.81 \$5.93 \$4.72	Return on Invested Capital 26.6% 23.7% 18.8% 13.5%	Revenue 972 1,134 1,293 1,216 1,392	232 321 397 398 422	Free Cash Flow 122 158 161 247 189	Net Debt 286 590 1,092 907 873	Market Capitalization 2,968 3,512 3,655 3,126 2,817
2022	\$4.43	13.3%	1,668	453	171	1,295	2,632
2023	\$2.61	10.3%	1,692	397	95	1,187	1,711
2024	\$1.40	7.1%	1,406	369	51	1,296	1,676
2017 - 2024	(\$1.46)	-19.4%	434	138	(71)	1,011	(1,292)
% Change	-51.0%	-73.1%	44.6%	59.4%	-58.1%	354.0%	-43.5%
CAGR	-9.7%	-	5.4%	6.9%	-11.7%	24.1%	-7.8%

Stockholders must act now before additional value is destroyed by entrenched Board

Fiscal years ended December 31
Figures in table derived from NGVT 10-Ks and Proxy Statements
Free Cash Flow defined as GAAP operating cash flow minus capital expenditures
Net Debt defined as total long-term debt minus cash and cash equivalents
Market Capitalization from Bloomberg as of market close February 24, 2025

Lack of Effective Leadership has Resulted in Worst-in-Class TSR



· NGVT has severely underperformed competitors

	From Start of			
Total Shareholder Return	Acquisition Spree	1-Year	3-Year	5-Year
NGVT	-42.0%	-4.2%	-32.8%	-5.3%
S&P 400 Index	80.0%	10.1%	22.0%	73.9%
S&P 400 Chemicals Index	23.9%	-5.1%	-0.8%	55.3%
S&P 400 Materials Index	57.7%	5.0%	12.8%	87.1%
NGVT vs S&P 400 Index	-122.0%	-14.3%	-54.8%	-79.1%
NGVT vs S&P 400 Chemicals	-65.9%	1.0%	-32.0%	-60.5%
NGVT vs S&P 400 Materials	-99.8%	-9.2%	-45.6%	-92.3%

Reconstituted Board will simplify core strategy and create immense shareholder value

Total shareholder returns derived via Bloomberg as of market close February 24, 2025

Start of Acquisition Spree defined as the period beginning with the closing of NGVT's acquisition of Georgia-Pacific's Pine Chemicals business on March 8, 2018 Performance periods relative to February 24, 2025 at 1-, 3-, and 5-year decrements

NGVT relative performance to a relevant index defined as NGVT total shareholder return minus total index return in the equivalent period

S&P 400 Midcap Index Bloomberg ticker: MID Index

S&P 400 Midcap Chemicals Index Bloomberg ticker: S4CHEM Index

S&P 400 Midcap Materials Index Bloomberg ticker: S4MATR Index

Lack of Effective Leadership has Resulted in Worst-in-Class TSR



- · Four entrenched legacy Board members with tenure approaching nine years
- · Those responsible for underperformance are least able to act objectively
- · Why should shareholders believe that the same mistakes won't continue under the status quo?

		Cumulative		
	Tenure	Relative	Shares	%
Board Member	Years	Return	Owned	Owned
Jean Blackwell	8.8	-73%	20,302	0.06%
Dan Sansone	8.8	-73%	19,649	0.05%
Luis Fernandez-Moreno	8.8	-73%	49,048	0.13%
Fred Lynch	8.8	-73%	22,302	0.06%
Karen Narwold	6.0	-138%	12,939	0.04%
Diane Gulyas	6.0	-136%	12,574	0.03%
Shon Wright	2.6	-63%	5,987	0.02%
Bruce Hoechner	2.0	-69%	4,771	0.01%
Kevin Willis	0.2	8%	2,386	0.01%
			Total	0.41%

Board refreshment with stockholder-focused directors is necessary to prevent further decline

Tenure measured as number of days between February 24, 2025 and each director's initial start date on the Board, divided by 365 days
Cumulative Relative Return measured as NGVT total shareholder return during each director's tenure minus the S&P 400 Midcap Index return during the same period
Shares owned sourced from latest Form 4 filing for each director


Percentage ownership calculated as director's shares owned divided by NGVT shares outstanding as of December 31, 2024

Succession Planning Failure



- · No credible succession plan existed as evidenced by the appointment of legacy Board member as Interim CEO
- · Highly excessive compensation package awarded to Mr. Fernandez-Moreno
- · Soon after filling the Interim CEO role with a former Ashland officer, NGVT added the CFO of Ashland, Kevin Willis, to the Board

Comparable Company CEO Salaries



Shareholder input on CEO selection is crucial for substantive change

Mr. Fernandez-Moreno's compensation package from October 2, 2024 8-K filing

Mr. Keohane's salary from Cabot's 2025 Proxy Statement filed January 24, 2025

Mr. Costa's salary from Eastman Chemical's 2024 Proxy Statement filed March 21, 2024


Mr. Knavish's salary from PPG's 2024 Proxy Statement filed March 21, 2024

Ms. Petz's salary from Sherwin-Williams' 2025 Preliminary Proxy Statement filed February 24, 2025

NGVT's Plan Further Obfuscates Corporate Strategy



- · Only after severe business declines has the Board decided to pivot and exit Industrial Specialties near the bottom
- · NGVT's plan likely amounts to a fire sale and weakens the remaining Road Technologies assets
- Mr. Fernandez-Moreno describes the sale as a "condominium." Importantly, this complex proposal would co-locate operations at the same site as the buyer, granting outside access to key facilities and introducing substantial new risk to the continuing business
- · The Board's plan would expose the IP and proprietary operations of the Company's retained market-leading pavement business
- · We believe shared plant operations would structurally impair Road Technologies, slow future growth, and permanently limit valuation




NGVT's co-location plan increases future risk to Road Technologies


Figures in table derived from NGVT 10-Ks, Proxy Stotements, and 2023 Analyst Day Presentation 2025 \$200 million revenue guidance from 4Q 2024 earnings presentation (\$180 million to \$200 million guidance range)

Performance Materials is a World-Class Business



- · Performance Materials is an industrial powerhouse
 - Industry leading profit margins
 - Low capital requirements
 - Stable revenue growth driven by increasing global regulation of gasoline vapor emissions





Standalone Performance Materials should command a significant valuation premium

Figures in table derived from NGVT 10-Ks and Proxy Statements

Solution: Simplify Portfolio and Reinvest in Performance Materials



Unveil Value of Performance Materials

- Fair valuation of Performance Materials is only possible with full exit of Performance Chemicals, not the piecemeal unwind proposed by the Board
- Divestment of Performance Chemicals utilizes tax assets generated through prior unsuccessful acquisitions

Apply Proceeds Evenly to Debt Reduction and Share Repurchase

Remaining Performance Materials and Capa Business

- We believe NGVT ex Performance Chemicals with best-in-class governance provisions will
 enjoy substantial multiple expansion due to unparalleled margins, low earnings
 volatility and stable market position
- Potential for NGVT shares to be worth \$124 per share and offer over 165% upside

Stop the Status Quo - Refresh Board with Stockholder Oriented Directors

- · Vision One has nominated four highly-qualified director candidates
- · Action is necessary to eliminate entrenchment

PC Sale Proceeds (@ 10x EBITDA)	680
Tax	(4)
Transaction Expenses	(7)
Net Proceeds	669
Share Repurchase (\$ million)	(335)
Average Repurchase Price	\$55.00
Shares Retired	(6)
Shares Outstanding	30
Net Debt	1,323
Debt Reduction	(335)
Net Debt	989
NGVT 2026 EBITDA	394
Multiple	12.0x
Enterprise Value	4,728
Net Debt	989
Equity Value	3,739
Shares Outstanding	30
Equity Value Per Share	\$123.53
NGVT Share Price	46.11
Equity Value Per Share	123.53
Value Creation	\$77.42
% Upside	168%
-	

Unveil the Performance Materials industrial powerhouse

\$68 million 2026 Vision One estimate of Performance Chemicals EBITDA

Taxes on sale assume a \$660 million tax basis in Performance Chemicals assets and a 21% tax rate

Share repurchases and debt paydown assumes de-minimis fees on transactions

\$394 million of NGVT EBITDA consists of \$44 million from Capa and \$350 million from Performance Materials

Vision One Pro-Forma Free Cash Flow Per Share calculated as \$394 million of EBITDA minus \$38 million of maintenance capital expenditures minus \$74 million of interest expense (7% interest rate on pro-forma net debt) minus \$55 million of tax expense minus \$13 million of finance lease expense divided by 30 million of pro-forma fully diluted shares outstanding Consensus 2026 Free Cash Flow Per Share derived from Bloomberg as of February 24, 2025

Vision One's Highly Qualified Board Nominees



Julio C. Acero

- · Director and Investment Analyst at Vision One since July 2022
- Formerly served from September 2021 to June 2022 as a Research Associate for
 Artisan Partners' \$30 billion Global Equity Fund covering the Industrials sector and as
 an Investment Analyst at Steel Partners LP, from September 2016 to July 2019, focused
 on public and private mid-cap equity investments across Consumer, Industrial, Energy,
 and Technology sectors
- Serves as a non-voting observer to the Board of Directors of Triumph Group, Inc. (NYSE: TGI)
- B.S. in Finance, Real Estate and Law from the California State Polytechnic University— Pomona, a Master of Accounting from USC Marshall School of Business, and an M.B.A from Northwestern University—Kellogg School of Management
- Detailed knowledge of financial accounting, managerial accounting, financial analysis, corporate strategy, company capitalization structures and the capital markets
- Broad business and investment experience in the industrial, aerospace, energy, consumer and technology sectors as well as experience with complex financing matters
- ✓ "Audit committee financial expert" under the rules of the SEC
- Independent

Courtney R. Mather

- · Chief Executive Officer and Chief Investment Officer of Vision One
- Formerly served as a Portfolio Manager and Managing Director of Icahn Capital from April 2014 to March 2020, and at Goldman Sachs & Co. from 1998 to 2012, most recently as Managing Director in private credit trading and investing, where he focused on identifying and analyzing investment opportunities for both Goldman Sachs and clients
- Director of Caesars Entertainment Corporation (Nasdaq: CZR) and currently serves on its Audit Committee, Compensation Committee, and Corporate Social Responsibility
- Director of Triumph Group, Inc. (NYSE: TGI) and currently serves as a member of its Audit Committee and its Finance & Strategy Committee
- · B.A. from Rutgers College
- Chartered Alternative Investment Analyst, Chartered Financial Analyst and Certified Financial Risk Manager professional designations
- Detailed knowledge of accounting and financial analysis, corporate strategy, risk governance, company capitalization structures and the capital markets
- Experience as a public company director in a variety of industries with a broad understanding of the responsibilities of public company boards, governance matters and public relations issues applicable to public companies
- ✓ "Audit committee financial expert" under the rules of the SEC.
- ✓ Independent

Vision One's Highly Qualified Board Nominees



Dr. Merri J. Sanchez


- Technical Fellow—Space Policy & Strategy with The Aerospace Corporation, providing technical and strategic advice on matters concerning civil, commercial, and government spaceflight programs since 2017
- · More than 40 years of spaceflight engineering and operations experience
- Previously served as the Chief Scientist of the U.S. Air Force Space Command from 2014 to 2017, as a Senior Director of a commercial space company from 2010 to 2014, and as a senior executive for the National Aeronautics and Space Administration from 1982 to 2010
- Bachelor of Science in Aerospace Engineering from Texas A&M University, a Master of
 Science in Physical Sciences (Planetary Geology) from the University of Houston —
 Clear Lake, a Master of Mechanical Engineering from the University of Houston, and a
 Doctor of Philosophy in Industrial Engineering (Human Factors) from the University of
 Houston
- Director of McEwen Mining Inc. (NYSE: MUX) since February 2022, including as a member of its Compensation, Nominating and Corporate Governance Committee.
- . Director of the Dee Howard International Education Foundation since November 2022
- Expertise in cutting edge science and technology as well as experience in operations, engineering, cybersecurity, safety, and risk management
- ✓ "Audit committee financial expert" under the rules of the SEC
- ✓ Independent

F. David Segal

- F. David Segal was Vice President of Investment Excellence for International Paper Company (NYSE: IP) from February 2021 to January 2025
- Led initiatives in creating shareholder value in all aspects including capital allocation, corporate strategy, investments, and operating performance
- · Bridged the divide between operator and investor perspectives
- Previously, Portfolio Manager of the Franklin Mutual Series Fund from 2002 to
 December 2020, with global research and investment responsibilities in companies in
 the industrials, automotive, paper and forest products, and defense sectors
- Previously a director of International Automotive Components Group, a leading global auto parts supplier, from 2006 to 2019
- B.A. from the University of Michigan and an M.B.A. from New York University's Stern School of Business
- · Chartered Financial Analyst professional designation
- Direct operating experience in paper and forest products business that is similar to NGVT's former parent company
- Prior experience as an investor with a long-term focus, industry and capital markets experience as well as experience in international operations, finance, capital allocation, corporate strategy, risk management, strategic transactions, and implementation of corporate initiatives
- ✓ "Audit committee financial expert" under the rules of the SEC
- Independent

Appendix: Historical NGVT Valuation Multiples





Shares are trading at record low valuation multiples reflecting lack of confidence in the Board

MGVT Valuation multiples: December 2016 through December 2024 trailing Price to Earnings, Price to Free Cash Flow, and Enterprise Value to EBITDA trailing multiples sourced from Bloomberg as of February 24, 2025. All three referenced valuation metrics at the lowest level in the Company's history (10.4x Price to Earnings, 8.8x Price to Free Cash Flow, 7.4x Enterprise Value to EBITDA as of market close February 24, 2025)

Appendix: Vision One's November 26, 2024 Letter to NGVT Board





Vision One Management Partners

November 26, 2024

Board of Directors of Ingevity Corporation ("Board") 4920 O'Hear Avenue, Suite 400 North Charleston, SC 29405 Attention: Rvan Fisher, Senior Vice President, General Counsel and Secretary Email: ryan.fisher@ingevity.com

Dear Ladies and Gentlemen:

We are writing on behalf of Vision One Fund, LP (collectively, with its affiliates, "Vision One"), a stockholder of Ingevity Corporation ("Ingevity" or the "Company").

We hold shares of Ingevity's common stock because we believe that the current share price significantly undervalues the Company's long-term earning potential. In our view, the Company is a compelling investment because of its dominant activated carbon platform and leading position in industrial adhesives, coatings, and resins.

However, we have serious concerns regarding Ingevity's long-term corporate strategy and capital allocation framework, which we believe have significantly contributed to its worst-in-class Total Shareholder Return ("TSR"). As a standalone public company, Ingevity has completed an excessive series of acquisitions that have complicated the Company's operations, corroded profit margins, and reduced returns on capital - all to the detriment of its stockholders.

Total Shareholder Return¹

	1-Year	3-Year	5-Year
Ingevity	23.0%	-35.8%	-47.4%
S&P 400 Chemicals Index	34.1%	27.2%	81.2%
S&P 400 Index	17.1%	8.0%	63.7%
Ingevity vs S&P 400 Chemicals	-11.196	-63.1%	-128.6%
Ingevity vs S&P 400 Index	5.9%	-43.8%	-111.0%

Unsuccessful Acquisitions

- Since 2017, Ingevity has cumulatively deployed \$1.2 billion across multiple acquisitions, including acquiring Georgia-Pacific's Pine Chemicals business, Perstorp Holding's Capa assets, and Ozark Materials, LLC.
- According to the Company's public disclosures, these acquisitions were expected to add \$121 million of EBITDA.2



- · Although some transactions increased the Company's EBITDA, which still fell short of projections provided by the Company's management, the Company's total debt ballooned by nearly \$1 billion during the same period, which dramatically increased the Company's financi leverage and risk.
- For example, Capa's subsequent performance declines are laid bare in the Advanced Polymer Technologies segment's ("APT") most recent earnings results. For the twelve-month period ended September 30, 2024, Capa profits were approximately half of what the business earned prior to being acquired by Ingevity. This result raises questions about management execution and, importantly, how the Company defines "core" vs. "non-core" assets. Unfortunately for Ingevity stockholders, the Capa purchase has destroyed economic value with an estimated Return on Invested Capital ("ROIC") of 1.1% that is well below the Company's 8.5% cost of capital.
- During this period, the Company's reported ROIC declined sharply from 26.6% to a paltry 9.3%.⁴
- Ingevity management has not adhered to or communicated clear return guidelines, risk parameters, or portfolio logic for its capital spending decisions, as evidenced by these strategic
- The added complexity in the Company's assets, higher volatility in its earnings, and weaker balance sheet and operating performance have resulted in worst-in-class peer returns.

- . In addition to its acquisition spree, Ingevity has spent \$723 million in capital expenditures and Ad9 million in share repurchases' at an average price of \$70.01 per share since 2017. With over \$2.4 billion of invested capital, the Company has delivered \$119 million of incremental EBITDA, which implies a cash return of only 4.996.
 Ingevity's free cash flow per share declined by 74% over this period.

 The provided in the provid
- We believe that the Company's consistently poor investment returns reflect that the Board has not provided sufficient oversight of management's corporate strategy. It is unclear whether the Board even established basic size, margin, or rationale limits for potential acquisitions, or whether these targets were prudently adjusted for execution risk when measured against internal investment opportunities.
- Given the Company's track record with acquisitions, we question whether Ingevity's Board possesses the financial expertise necessary to effectively evaluate material corporate actions and strategic initiatives.

Based on Bloomberg data as of market close November 26, 2024. Total Shareholder Return includes dividends reinv

Treasury rate.

Ingevity's estimate of target EBITDA at the time of acquisition

¹ Capa ROIC calculated as \$6 million of NOPAT for the twelve-month period ended September 30, 2024 divided by \$557 million of net debt acquisition financing: Bloomberg estimate for NOVT weighted average cost of capital as of November 26, 2024.

¹ Estimated for the twelve-month period ended September 30, 2024.

¹ Estimated for the twelve-month period ended September 30, 2024.

¹ Estimated for the twelve-month period ended September 30, 2024.

¹ Incremental IBITOA colosabed from year end 2017 to the twelve-month period ended September 30, 2024 divided by the sum of \$1.2 billion in acquaitions, \$723 million in capital expenditures, and \$489 million in share repurchases from year end 2017 to the twelve-month period ended September 30, 2024.

² Calculated as \$2.86 per share of FCF at year end 2017 compared to \$0.74 per share of FCF at the twelve-month period ended September 30, 2024.

Appendix: Vision One's November 26, 2024 Letter to NGVT Board





Hasty Leadership Decisions

- We do not believe that the replacement of the Company's prior CEO with Mr. Fernandez-Moreno is enough to restore investor confidence in Ingevity.
- . While Mr. Fernandez-Moreno's industry expertise is commendable, the compensation awarded to him by the Board appears excessive - an annual base salary of \$3 million for an Interim CEO is an outlier for a company of Ingevity's size.

 The median annual base salary for the CEOs of Cabot Corporation, Eastman Chemical
- Company, PPG Industries, Inc., and Sherwin-Williams Co., companies with a median market capitalization of \$20 billion,* is \$1.2 million,* nearly 60% below what Mr. Fernandez-Moreno earns in a temporary and yet unproven role.

Lack of Alignment with Stockholder

- We believe that there is an absence of accountability within the Board itself, with no genuine representation on the Board of stockholder interests. Directors have minimal personal vestment or "skin in the game," as insider ownership stands at just 0.47% in the aggregate, which is alarmingly low given the long tenures of several Board members.
- Two directors have served on the Board for almost nine years, which is excessively long given the Company's performance. Proxy advisory firms advocate that tenures of that duration may
- "potentially compromise a director's independence." and we agree.

 Ingevity's poor TSR indicates that entrenched directors have hindered the infusion of fresh perspectives necessary for effective governance and value creation for all stockholders.

We look forward to engaging in a constructive dialogue with the Board about how to pursue several value-creating opportunities. We believe that the Board should take affirmative steps to improve its overall commitment to stockholder rights, corporate governance and to engage in a strategic review of its operations, focused on highlighting the value of its Performance Materials segment ("PM").

Improve Stockholder Representation

Based on the unsuccessful acquisitions, inadequate oversight, hasty decisions, and lack of alignment with stockholders, we believe that the Company's stockholders lack confidence in the Board's ability to manage the business with appropriate oversight. To ensure the Company's future success and restore investor confidence, it is imperative that the Board appoint additional individuals who will directly represent the interests of all the Company's stockholders. We propose that you add a director who is a representative of one of your stockholders.

Improve Corporate Governance

The stockholders of Ingevity reasonably expect and deserve best-in-class stockholder rights and



protections. Corporate governance practices are a key driver of long-term share price performance Recent studies confirm that companies with poor governance provisions underperformed those with better governance by nearly 50% over a 10-year period.11

We urge the Board to prioritize corporate governance by adopting amendments to the Company's organizational documents that 1) allow stockholders to act by written consent without holding a meeting, 2) reduce the required ownership threshold to 10% for stockholders to call special meetings and 3) establish director term limits. The Company's recent management turnover provides a timely opportunity for the Board to instill best practices and improve its engagement with the Company's stockholde

Review Strategic Alternatives

We believe that due to the deep conglomerate discount embedded in Ingevity's share price, the Company's industry-leading PM business is radically undervalued by the market despite its above-GDP revenue growth, high EBITDA margins and favorable regulatory position. The current discount presents a unique opportunity for the Board to create immense stockholder value by highlighting the superior economic characteristics and robust financial profile of PM. To capitalize on this opportunity, we recommend that the Board initiate a strategic review process to explore alternatives for the Performance Chemicals segment ("PC") and APT. This review should consider all available options including a tax-efficient sale, an IPO, or a non-taxable spin-off distribution.

In our view, the separation of PM from PC and APT is a feasible strategy, given that their production processes are largely distinct from one another. PM has different raw material requirements, un global regulatory drivers, distinct competitors, and varying end-market cyclicality relative to the Company's other businesses.

We believe that a standalone PM would command a meaningful valuation premium to competitors driven by the global government regulation of gasoline vapor emissions, its high and stable EBITDA margins, and its overall operating leverage that drives profit higher as production scales. Peer ations indicate that a standalone PM could be worth more than the current market value of all of Ingevity.

At the current ingevity share price, we believe that the market discounts the value of PM by at least 50%.¹² The Board is therefore obligated to consider actions to correct this steep undervaluation. Based on our assumptions, potential strategic alternatives for PC and APT could more than double Ingevity's share price in the near term, as compared to the benefits and risks associated with maintaining the Company's current corporate strategy.

We urge the Board to undertake a strategic alternatives process for PC and APT, as well as establish a Board committee to maintain active Board oversight of the process.

Bloomberg as of November 26, 2024.
 As reported in each company's proxy statem

ks reported in each company's proxy statement. "ISS Governance QuickScore 2.0," issgovernance.com

[&]quot;"Corporate Governance and Company Performance," Grant Thornton, 2019, https://www.grantthornton.co.uk." Board on Vision Cher's estimate for 2036 EBITON of 3327 million for PM, \$104 million for PC, \$43 million for APT, and specialty chemic. press trading multiples of 6s to 8s, 4th tis visitation range PC and APT are worth a combined \$925 million in \$12.0 billion and imply \$1.9 billion to \$32.0 billion for PM, which is approximately half of our fair value estimate. Total Enterprise Value is calculated as market value as of November 28, 2020 by lane red debt.

Appendix: Vision One's November 26, 2024 Letter to NGVT Board





Given the proximity to the Company's deadline for receipt of stockholder nominations for director candidates pursuant to the Company's Fourth Amended and Restated Bylaws (the "Bylaws"), we look forward to discussing our views with the Company as soon as possible. This letter constitutes Vision One's request in writing to the Corporate Secretary of the Company for copies of the forms of any documents that a proposed director nominee is required to furnish in connection with his or her nomination in accordance with the Bylaws. To the extent that the Company may require any proposed nominee to furnish additional information to determine the eligibility of such proposed nominee to serve as an independent director of the Company that is not otherwise specified in the Bylaws, this letter hereby acts as the formal request for any such additional information requests.

We urge the Board to conduct a thorough review of its composition, establish mechanisms for stronger stockholder representation, and explore strategic alternatives for PC and APT. Ingevity has the opportunity to demonstrate its commitment to its stockholders and rebuild investor confidence by providing them with a high-quality, stable business that compounds capital above-market for years to come.

We are excited about the future of Ingevity and look forward to continuing our discussions with the Board. We are prepared to meet at your convenience.

Sincerely

Courtney R. Mather Chief Investment Officer Vision One Fund, LP

Julio C. Acero Director, Investment Analyst

